Clinical Trials Logo

S-1 clinical trials

View clinical trials related to S-1.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06427005 Recruiting - Fruquintinib Clinical Trials

Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC

Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

Based on the FRECO-2 study, Fruquintinib has become one of the standard third-line treatments for advanced colorectal cancer; however, its objective response rate (ORR) remains low. Our previous studies have shown that the combination of raltitrexed and S-1 -/+ bevacizumab is effective and provides a significant survival benefit in patients with metastatic colorectal cancer (mCRC) who are refractory to standard treatments. This study aims to evaluate the efficacy and safety of combining Fruquintinib with S-1 and raltitrexed in these patients.